Titan Pharmaceuticals Third Quarter 2014 Financial Results
Friday, November 14, 2014 - 8:00AM PT | 11:00AM ETParticipant Toll Free: 888-637-7707 | Participant Passcode: 9367783
THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=101001
Braeburn expands portfolio for opioid addiction treatment, potentially adding up to $50 million to future Titan royalties
South San Francisco, CA – Nov. 20, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.
Titan Management Team to Host Conference Call Nov. 14 at 11 a.m. EST
South San Francisco, CA – Nov. 13, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.
South San Francisco, CA – Nov. 11, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
South San Francisco, CA – November 7, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that it will host a live conference call at 11 a.m. EST / 8 a.m. PST on Friday, Nov. 14, 2014 to discuss the company’s financial results as of Sept. 30, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the third quarter and financial results will be included in a press release to be issued prior to the call.
Probuphine is Titan’s novel subdermal implant formulation designed using its ProNeura technology to deliver six months of buprenorphine hydrochloride (“buprenorphine”) following a single treatment. Probuphine is being developed for the treatment of opioid dependence...
Read More... »»
Probuphine® Program Update
Oct. 15, 2014
Recent $10.5 million financing supports new product development and ongoing operations through 2016.
As announced in late September, patient enrollment in the Phase 3 study of Probuphine®, the company’s investigational subdermal implant ...
Read More... »»
Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of central nervous system (“CNS”) disorders.
Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.5 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication...
Read more... » »